Payden & Rygel’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-120,900
Closed -$10.7M 144
2023
Q2
$10.7M Buy
120,900
+13,400
+12% +$1.15M 0.75% 64
2023
Q1
$8.67M Buy
107,500
+106,000
+7,067% +$8.64M 0.51% 74
2022
Q4
$117K Hold
1,500
0.01% 130
2022
Q3
$121K Sell
1,500
-45,400
-97% -$4.08M 0.01% 131
2022
Q2
$4.21M Sell
46,900
-276,400
-85% -$28M 0.25% 72
2022
Q1
$35.9M Buy
323,300
+195,130
+152% +$20.6M 1.81% 15
2021
Q4
$13.3M Buy
128,170
+120,470
+1,565% +$14M 0.61% 71
2021
Q3
$965K Hold
7,700
0.05% 92
2021
Q2
$956K Sell
7,700
-224,680
-97% -$28.2M 0.05% 97
2021
Q1
$27.5M Buy
232,380
+6,300
+3% +$738K 1.28% 38
2020
Q4
$26.5M Buy
226,080
+3,980
+2% +$438K 1.36% 38
2020
Q3
$23.1M Sell
222,100
-130,800
-37% -$13.1M 1.37% 37
2020
Q2
$32.4M Sell
352,900
-11,400
-3% -$1.09M 2.06% 12
2020
Q1
$32.9M Buy
364,300
+29,958
+9% +$3.19M 2.37% 12
2019
Q4
$37.9M Buy
334,342
+32,400
+11% +$3.56M 2.37% 9
2019
Q3
$32.8M Buy
301,942
+81,642
+37% +$8.52M 2.23% 16
2019
Q2
$21.5M Buy
220,300
+7,400
+3% +$676K 1.47% 31
2019
Q1
$19.4M Buy
+212,900
New +$19.1M 1.42% 34
2016
Q1
Sell
-226
Closed -$17K 191
2015
Q4
$17K Buy
+226
New +$17K ﹤0.01% 148

Other funds holding MDT

Payden & Rygel's MDT Position: Q3 2023 in Review

Payden & Rygel sold out of Medtronic (MDT) in Q3 2023, closing a stake of 120,900 shares — an estimated $10.7M sold.

Payden & Rygel first reported a position in MDT in Q4 2015 and held it in 19 quarters. The position peaked at $37.9M in Q4 2019. 1,970 funds tracked by Wall St. Rank hold MDT as of Q3 2023.

  • Payden & Rygel reported no remaining Medtronic position as of Q3 2023 after selling out during the quarter.
  • Payden & Rygel sold 120,900 Medtronic shares in Q3 2023, an estimated $10.7M.
  • Payden & Rygel first reported a position in Medtronic in Q4 2015 and held it in 19 quarters.
  • Payden & Rygel's Medtronic position peaked at $37.9M in Q4 2019.
  • 1,970 funds tracked by Wall St. Rank held Medtronic as of Q3 2023.

Based on Payden & Rygel's 13F filing for Q3 2023, filed 7 Oct 2024.